BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Meridian Bioscience, Inc. (“Meridian” or the “Company”) (NASDAQ: VIVO) investors concerning the Company and its officers’ possible violations of federal securities laws.
On May 17, 2017, the U.S. Food and Drug Administration (“FDA”) issued a field safety notice advising that customers discontinue use of Magellan’s lead testing system using venous blood samples. Then, on October 23, 2017, Magellan received a warning letter from the FDA following an inspection. In a press release, the FDA stated that the warning letter was the result of “several violations of federal law” by Magellan, including “marketing significantly modified versions of two of its blood lead testing systems without the FDA’s required clearance or approval and failing to submit medical device reports to the FDA after becoming aware of customer complaints involving discrepancies in blood lead test results.”
On this news, shares of Meridian fell sharply, thereby injuring investors.
If you purchased Meridian securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.